Cancer-killing, decoy-resistant interleukin-18

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Interleukin-18 (IL-18) is a cytokine crucial for immune responses.
• Current IL-18 therapies face challenges with decoy receptor neutralization.
• Developing resistant IL-18 variants is essential for effective cancer immunotherapy.

Purpose of the Study:

• To engineer a decoy-resistant variant of interleukin-18 (IL-18).
• To evaluate the antitumor activity of the engineered IL-18.
• To assess the translational potential of this novel immunotherapy agent.

Main Methods:

• Protein engineering techniques were employed to modify IL-18.
• In vitro assays were used to confirm resistance to decoy receptors.
• In vivo studies in tumor models assessed antitumor efficacy.

Main Results:

• The engineered IL-18 variant demonstrated potent resistance to decoy receptors.
• Significant inhibition of tumor growth was observed in preclinical models.
• The engineered IL-18 showed favorable safety and pharmacokinetic profiles.

Conclusions:

• Engineered decoy-resistant IL-18 exhibits strong antitumor potential.
• This approach offers a promising strategy for enhancing cancer immunotherapy.
• Further clinical development is warranted for this novel therapeutic agent.